Search

Your search keyword '"Derumeaux G"' showing total 511 results
Start Over Author "Derumeaux G"
511 results on '"Derumeaux G"'

4. Determinants of atrial arrhythmia in Sickle cell anemia

Author

Sadraoui, Z., primary, Regragui, C., additional, Iles, S., additional, De Luna, G., additional, Amorouayeche, Z., additional, Boyer, L., additional, Alassaad, L., additional, Guillet, H., additional, Laurent, S., additional, Lellouche, N., additional, Derumeaux, G., additional, Bartolucci, P., additional, and D’Humières, T., additional

Published
2024
Full Text
View/download PDF

8. Immune response to pertussis vaccine in COPD patients

Author

Feredj, E., primary, Wiedemann, A., additional, Krief, C., additional, Maitre, B., additional, Derumeaux, G., additional, Chouaid, C., additional, Corvoisier, P. Le, additional, Lacabaratz, C., additional, Gallien, S., additional, Lelièvre, JD, additional, and Boyer, L., additional

Published
2022
Full Text
View/download PDF

17. Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA)

Author

Cenko, E, Badimon, L, Bugiardini, R, Claeys, MJ, De Luca, G, de Wit, C, Derumeaux, G, Dorobantu, M, Duncker, DJ, Eringa, EC, Gorog, DA, Hassager, C, Heinzel, FR, Huber, K, Manfrini, O, Milicic, D, Oikonomou, E, Padro, T, Trifunovic-Zamaklar, D, Vasiljevic-Pokrajcic, Z, Vavlukis, M, Vilahur, G, and Tousoulis, D

Subjects
post-acute COVID-19, SARS-CoV-2, inflammation, Myocardial injury, COVID-19, microcirculation, Cardiovascular disease, Infection, cytokines, endothelial dysfunction, thrombosis
Abstract

The cardiovascular system is significantly affected in coronavirus disease-19 (COVID-19). Microvascular injury, endothelial dysfunction, and thrombosis resulting from viral infection or indirectly related to the intense systemic inflammatory and immune responses are characteristic features of severe COVID-19. Pre-existing cardiovascular disease and viral load are linked to myocardial injury and worse outcomes. The vascular response to cytokine production and the interaction between severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and angiotensin-converting enzyme 2 receptor may lead to a significant reduction in cardiac contractility and subsequent myocardial dysfunction. In addition, a considerable proportion of patients who have been infected with SARS-CoV-2 do not fully recover and continue to experience a large number of symptoms and post-acute complications in the absence of a detectable viral infection. This conditions often referred to as 'post-acute COVID-19' may have multiple causes. Viral reservoirs or lingering fragments of viral RNA or proteins contribute to the condition. Systemic inflammatory response to COVID-19 has the potential to increase myocardial fibrosis which in turn may impair cardiac remodelling. Here, we summarize the current knowledge of cardiovascular injury and post-acute sequelae of COVID-19. As the pandemic continues and new variants emerge, we can advance our knowledge of the underlying mechanisms only by integrating our understanding of the pathophysiology with the corresponding clinical findings. Identification of new biomarkers of cardiovascular complications, and development of effective treatments for COVID-19 infection are of crucial importance.

Published
2021

24. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism

Author

Pristipino C, Sievert H, D'Ascenzo F, Mas JL, Meier B, Scacciatella P, Hildick-Smith D, Gaita F, Toni D, Kyrle P, Thomson J, Derumeaux G, Onorato E, Sibbing D, Germonpré P, Berti S, Chessa M, Bedogni F, Dudek D, Hornung M, Zamorano J, European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Stroke Organisation (ESO), European Heart Rhythm Association (EHRA), European Association for Cardiovascular Imaging (EACVI), Association for European Paediatric and Congenital Cardiology (AEPC), ESC Working group on GUCH, ESC Working group on Thrombosis, European Haematological Society (EHA)., Pristipino, C, Sievert, H, D'Ascenzo, F, Mas, Jl, Meier, B, Scacciatella, P, Hildick-Smith, D, Gaita, F, Toni, D, Kyrle, P, Thomson, J, Derumeaux, G, Onorato, E, Sibbing, D, Germonpré, P, Berti, S, Chessa, M, Bedogni, F, Dudek, D, Hornung, M, Zamorano, J, European Association of Percutaneous Cardiovascular Interventions, (EAPCI), European Stroke Organisation, (ESO), European Heart Rhythm Association, (EHRA), European Association for Cardiovascular Imaging, (EACVI), Association for European Paediatric and Congenital Cardiology, (AEPC), ESC Working group on, Guch, ESC Working group on, Thrombosi, and European Haematological Society, (EHA).

Published
2019

27. Predictive value of early cardiac mri functional and geometric indexes on adverse left ventricular remodelling in anterior STEMI patients. A report from the CIRCUS study

Author

Pezel, T., primary, Besseyre Des Horts, T., additional, Schaaf, M., additional, Croisille, P., additional, Biere, L., additional, Garcia Dorado, D., additional, Jossan, C., additional, Roubille, F., additional, Tri Cung, T., additional, Prunier, F., additional, Elbaz, M., additional, Amaz, C., additional, Derumeaux, G., additional, De Poli, F., additional, Hovassse, T., additional, Gilard, M., additional, Bergerot, C., additional, Thibault, H., additional, Ovize, M., additional, and Mewton, N., additional

Published
2021
Full Text
View/download PDF

38. Clinical evaluation of cardiovascular devices: principles, problems, and proposals for European regulatory reform: Report of a policy conference of the European Society of Cardiology†

Author

Fraser, Alan G., Daubert, Jean-Claude, Van de Werf, Frans, Estes, N.A. Mark, III, Smith, Sidney C., Jr, Krucoff, Mitchell W., Vardas, Panos E., Komajda, Michel, Anker, SD, Auricchio, A, Bailey, S, Bonhoeffer, P, Borggrefe, M, Brodin, L-Å, Bruining, N, Buser, P, Butchart, E, Calle Gordo, J, Cleland, J, Danchin, N, Daubert, JC, Degertekin, M, Demade, I, Denjoy, N, Derumeaux, G, Di Mario, C, Dickstein, K, Dudek, D, Estes, NA, Farb, A, Flotats, A, Fraser, AG, Gueret, P, Israel, C, James, S, Kautzner, J, Komajda, M, Krucoff, MW, Lombardi, M, Marwick, T, Mioulet, M, OʼKelly, S, Perrone-Filardi, P, Rosano, G, Rosenhek, R, Sabate, M, Smith, SC, Swahn, E, Tavazzi, L, Van de Werf, F, van der Velde, E, van Herwerden, L, Vardas, PE, Voigt, J-U, Weaver, D, and Wilmshurst, P.

Published
2011
Full Text
View/download PDF

39. Évaluation prospective des comorbidités cardio-métaboliques dans une cohorte de patients atteints de dilatations des bronches non mucoviscidosiques

Author

Bonnefoy, V., primary, Boyer, L., additional, Audureau, E., additional, Bassinet, L., additional, Zebachi, S., additional, Douvry, B., additional, Monnet, I., additional, Mangiapan, G., additional, Touboul, C., additional, Ernande, L., additional, Boudjemaa, A., additional, Derumeaux, G., additional, Housset, B., additional, Maitre, B., additional, and Schlemmer, F., additional

Published
2020
Full Text
View/download PDF

42. CCR2- and CCR5-Mediated Crosstalk Between Macrophages and Pulmonary-Artery Smooth Muscle Cells Drives Pulmonary Hypertension

Author

Abid, S., primary, Marcos, E., additional, Parpaleix, A., additional, Amsellem, V., additional, Breau, M., additional, Houssaini, A., additional, Vienney, N., additional, Validire, P., additional, Lefevre, M., additional, Derumeaux, G., additional, Evans, S.M., additional, Hubeau, C., additional, Delcroix, M., additional, Quarck, R., additional, Adnot, S., additional, and Lipskaia, L., additional

Published
2019
Full Text
View/download PDF

43. Consequence of Desmin gene mutation on development of chronic hypoxic pulmonary hypertension in mice

Author

Abid, S., primary, Houssaini, A., additional, Born, E., additional, Ternacle, J., additional, Hovhannisyan, Y., additional, Beaulieu, D., additional, Marcos, E., additional, Li, Z., additional, Marthan, R., additional, Agbulut, O., additional, Derumeaux, G., additional, Adnot, S., additional, Guibert, C., additional, and Lipskaia, L., additional

Published
2019
Full Text
View/download PDF

46. Exercise rescues obesity-induced adipose tissue premature aging and restores cardio-metabolic homeostasis

Author

Pini, M., primary, Czibik, G., additional, Sawaki, D., additional, Mercedes, R., additional, Ternacle, J., additional, Henegar, C., additional, Braud, L., additional, Mezdari, Z., additional, Radu, C., additional, Dubois-Randé, J.L., additional, Adnot, S., additional, Foresti, R., additional, Motterlini, R., additional, and Derumeaux, G., additional

Published
2018
Full Text
View/download PDF

49. Comparison of right ventricular septal pacing and right ventricular apical pacing in patients receiving cardiac resynchronization therapy defibrillators: the SEPTAL CRT Study

Author

Leclercq C, Sadoul N, Mont L, Defaye P, Osca J, Mouton E, Isnard R, Habib G, Zamorano J, Derumeaux G, Fernandez-Lozano I, and Septal Crt, Study Investigators

Subjects
Cardiac resynchronization therapy, Left ventricular end-systolic volume, Right ventricular defibrillation lead, Right ventricular lead position
Abstract

Aims Cardiac resynchronization therapy (CRT) is a recommended treatment of heart failure (HF) patients with depressed left ventricular ejection fraction and wide QRS. The optimal right ventricular (RV) lead position being a matter of debate, we sought to examine whether RV septal (RVS) pacing was not inferior to RV apical (RVA) pacing on left ventricular reverse remodelling in patients receiving a CRT-defibrillator. Methods and results Patients (n = 263, age = 63.4 +/- 9.5 years) were randomly assigned in a 1: 1 ratio to RVS (n = 131) vs. RVA (n = 132) pacing. Left ventricular end-systolic volume (LVESV) reduction between baseline and 6 months was not different between the two groups (-25.3 +/- 39.4 mL in RVS group vs. -29.3 +/- 44.5 mL in RVA group, P = 0.79). Right ventricular septal pacing was not non-inferior (primary endpoint) to RVA pacing with regard to LVESV reduction (average difference = -4.06 mL; P = 0.006 with a 220 mL non-inferiority margin). The percentage of 'echo-responders' defined by LVESV reduction >15% between baseline and 6 months was similar in both groups (50%) with no difference in the time to first HF hospitalization or death (P = 0.532). Procedural or device-related serious adverse events occurred in 68 patients (RVS = 37) with no difference between the two groups (P = 0.401). Conclusion This study demonstrates that septal RV pacing in CRT is non-inferior to apical RV pacing for LV reverse remodelling at 6 months with no difference in the clinical outcome. No recommendation for optimal RV lead position can hence be drawn from this study.

Published
2016

50. The European CRT Survey: 1 year (9-15 months) follow-up results

Author

Bogale, N, Priori, S, Cleland, Jg, Brugada, J, Linde, C, Auricchio, A, van Veldhuisen DJ, Limbourg, T, Gitt, A, Gras, D, Stellbrink, C, Gasparini, M, Metra, Marco, Derumeaux, G, Gadler, F, Buga, L, Dickstein, K, Scientific Committee, National Coordinators, Investigators, University of Zurich, Bogale, Nigussie, Faculteit Medische Wetenschappen/UMCG, and Cardiovascular Centre (CVC)

Subjects
Male, Cardiac resynchronization therapy (CRT), medicine.medical_treatment, Severity of Illness Index, law.invention, Cardiac Resynchronization Therapy, Randomized controlled trial, Risk Factors, law, Atrial Fibrillation, Multicenter Studies as Topic, Survey, Randomized Controlled Trials as Topic, 1 year (9-15 months) follow-up, CARDIAC-RESYNCHRONIZATION THERAPY, education.field_of_study, Data Collection, Atrial fibrillation, Middle Aged, Implantable cardioverter-defibrillator, CHRONIC HEART-FAILURE, Europe, Hospitalization, Outcome and Process Assessment, Health Care, Treatment Outcome, Heart Function Tests, cardiovascular system, Cardiology, Female, Cardiology and Cardiovascular Medicine, CLINICAL-TRIALS, medicine.medical_specialty, IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR, CARE-HF TRIAL, Population, Cardiac resynchronization therapy, 610 Medicine & health, Heart failure, Risk Assessment, 11171 Cardiocentro Ticino, 2705 Cardiology and Cardiovascular Medicine, Internal medicine, Severity of illness, medicine, Humans, PERMANENT ATRIAL-FIBRILLATION, Cardiac Resynchronization Therapy Devices, ATRIOVENTRICULAR JUNCTION ABLATION, cardiovascular diseases, education, Aged, business.industry, LONG-TERM SURVIVAL, medicine.disease, Survival Analysis, RANDOMIZED-TRIAL, Clinical trial, CONDUCTION DELAY, business, Follow-Up Studies
Abstract

Aims The European CRT Survey is a joint initiative of the Heart Failure Association (HFA) and the European Heart Rhythm Association (EHRA) of the European Society of Cardiology evaluating the contemporary implantation practice of cardiac resynchronization therapy (CRT) in Europe. Methods and results Patients who had a successful CRT implantation were enrolled from 141 centres in 13 countries between November 2008 and June 2009. Baseline demographics, clinical and implantation data were collected, with a follow-up of ∼1 year (9–15 months). The current report describes clinical outcomes including symptom severity, cardiovascular (CV) hospitalization, and survival. A total of 2438 patients were enrolled, and follow-up data were acquired from 2111 patients (87%). The population included important groups of patients poorly represented in randomized controlled trials, including very elderly patients and those with prior device implantation, atrial fibrillation, and/or QRS duration

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results